PriceTargets.com logo

Zoetis - ZTS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $215.22
  • Forecasted Upside: 30.56%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 2 Strong Buy Ratings
$164.84 As of 12/20/2024 06:31 PM ET
▲ +1.32 (0.81%)

This chart shows the closing price for ZTS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zoetis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZTS

Analyst Price Target is $215.22
▲ +30.56% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Zoetis in the last 3 months. The average price target is $215.22, with a high forecast of $230.00 and a low forecast of $196.00. The average price target represents a 30.56% upside from the last price of $164.84.

This chart shows the closing price for ZTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 11 polled investment analysts is to buy stock in Zoetis. This rating has held steady since February 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 2 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 2 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/9/2024UBS GroupInitiated CoverageNeutral$196.00
12/2/2024Leerink PartnrsUpgradeStrong-Buy
12/2/2024Leerink PartnersInitiated CoverageOutperform$215.00
10/11/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$225.00 ➝ $230.00
9/18/2024Stifel NicolausBoost TargetBuy ➝ Buy$200.00 ➝ $210.00
8/27/2024Stifel NicolausReiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
8/14/2024Piper SandlerBoost TargetOverweight ➝ Overweight$195.00 ➝ $210.00
8/12/2024BTIG ResearchBoost TargetBuy ➝ Buy$220.00 ➝ $225.00
8/9/2024ArgusUpgradeStrong-Buy
8/5/2024Stifel NicolausBoost TargetBuy ➝ Buy$180.00 ➝ $200.00
7/25/2024BTIG ResearchInitiated CoverageBuy$220.00
5/8/2024HSBCLower TargetBuy ➝ Buy$230.00 ➝ $225.00
5/6/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$223.00 ➝ $196.00
4/30/2024Stifel NicolausLower TargetBuy ➝ Buy$195.00 ➝ $180.00
4/23/2024BarclaysLower TargetOverweight ➝ Overweight$260.00 ➝ $230.00
4/16/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$220.00 ➝ $195.00
4/2/2024Stifel NicolausLower TargetBuy ➝ Buy$215.00 ➝ $195.00
2/20/2024Piper SandlerBoost TargetOverweight ➝ Overweight$215.00 ➝ $220.00
2/14/2024BarclaysBoost TargetOverweight ➝ Overweight$255.00 ➝ $260.00
1/17/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$190.00 ➝ $226.00
1/12/2024Stifel NicolausBoost TargetBuy$195.00 ➝ $215.00
12/19/2023Jefferies Financial GroupReiterated RatingBuy$230.00
12/7/2023BNP ParibasInitiated CoverageOutperform$237.00
11/6/2023Piper SandlerBoost TargetOverweight ➝ Overweight$210.00 ➝ $215.00
10/30/2023Stifel NicolausLower TargetBuy ➝ Buy$205.00 ➝ $195.00
10/5/2023Piper SandlerLower Target$220.00 ➝ $210.00
9/19/2023ArgusBoost Target$190.00 ➝ $201.00
9/12/2023Stifel NicolausReiterated RatingBuy ➝ Buy$205.00
9/6/2023HSBCInitiated CoverageBuy$230.00
8/28/2023Stifel NicolausBoost TargetBuy ➝ Buy$195.00 ➝ $205.00
8/14/2023Piper SandlerBoost TargetOverweight ➝ Overweight$210.00 ➝ $220.00
8/9/2023The Goldman Sachs GroupBoost TargetBuy ➝ Buy$204.00 ➝ $213.00
5/8/2023Piper SandlerLower Target$220.00 ➝ $210.00
4/11/2023Bank Of America (Bofa)Boost TargetBuy ➝ Buy$180.00 ➝ $200.00
2/21/2023BarclaysBoost TargetOverweight$250.00 ➝ $260.00
11/15/2022Morgan StanleyLower TargetOverweight$264.00 ➝ $248.00
11/4/2022The Goldman Sachs GroupLower TargetBuy$207.00 ➝ $180.00
11/3/2022William BlairReiterated RatingOutperform
10/17/2022JPMorgan Chase & Co.Lower TargetOverweight$250.00 ➝ $225.00
8/5/2022William BlairReiterated RatingOutperform
7/21/2022The Goldman Sachs GroupLower TargetConviction-Buy ➝ Buy$208.00 ➝ $202.00
7/11/2022Piper SandlerInitiated CoverageOverweight$205.00
6/24/2022Stifel NicolausLower TargetBuy$275.00 ➝ $225.00
5/19/2022The Goldman Sachs GroupLower TargetBuy$237.00 ➝ $208.00
3/9/2022CitigroupLower TargetNeutral$232.00 ➝ $208.00
12/20/2021CitigroupBoost TargetNeutral$184.00 ➝ $232.00
11/18/2021Morgan StanleyInitiated CoverageOverweight$264.00
11/5/2021BarclaysBoost TargetOverweight$235.00 ➝ $240.00
8/25/2021ArgusBoost TargetBuy$195.00 ➝ $225.00
8/9/2021Credit Suisse GroupBoost TargetOutperform$206.00 ➝ $230.00
8/6/2021BarclaysBoost TargetOverweight$208.00 ➝ $235.00
7/16/2021Raymond JamesDowngradeOutperform ➝ Market Perform
7/13/2021Cantor FitzgeraldBoost TargetOverweight$210.00 ➝ $238.00
5/28/2021ArgusBoost TargetBuy$185.00 ➝ $195.00
5/12/2021CitigroupBoost Target$175.00 ➝ $184.00
5/7/2021Raymond JamesBoost TargetOutperform$166.00 ➝ $192.00
5/7/2021BarclaysBoost TargetOverweight$200.00 ➝ $208.00
3/8/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$166.00
3/8/2021Bank of AmericaUpgradeNeutral ➝ Buy$180.00
2/17/2021Credit Suisse GroupBoost Target$197.00 ➝ $203.00
11/13/2020Morgan StanleyBoost TargetEqual Weight$167.00 ➝ $174.00
11/12/2020Truist FinancialBoost Target$160.00 ➝ $170.00
11/6/2020BarclaysBoost TargetOverweight$175.00 ➝ $189.00
9/21/2020Atlantic SecuritiesInitiated CoverageOverweight$191.00
8/20/2020Morgan StanleyBoost TargetNeutral ➝ Equal Weight$125.00 ➝ $167.00
8/14/2020Edward JonesUpgradeHold ➝ Buy
8/12/2020G.ResearchDowngradeBuy ➝ Hold
8/12/2020GabelliDowngradeBuy ➝ Hold
8/10/2020Truist FinancialBoost TargetNeutral ➝ Hold$112.00 ➝ $160.00
8/10/2020CitigroupBoost TargetNeutral$146.00 ➝ $160.00
8/7/2020Stifel NicolausBoost TargetTop Pick ➝ Buy$155.00 ➝ $170.00
7/30/2020CitigroupBoost TargetNeutral$131.00 ➝ $146.00
7/20/2020Bank of AmericaBoost TargetNeutral$135.00 ➝ $150.00
6/3/2020ArgusReiterated RatingBuy
5/27/2020Jefferies Financial GroupInitiated CoverageBuy$152.00
5/18/2020Credit Suisse GroupReiterated RatingBuy$147.00
5/8/2020UBS GroupLower TargetNeutral$146.00 ➝ $126.00
5/8/2020CitigroupLower TargetNeutral$139.00 ➝ $131.00
5/7/2020BarclaysBoost TargetOverweight$129.00 ➝ $140.00
4/2/2020Morgan StanleyLower TargetEqual Weight$148.00 ➝ $125.00
3/31/2020G.ResearchUpgradeHold ➝ Buy
2/28/2020The Goldman Sachs GroupReiterated RatingBuy$162.00
2/19/2020UBS GroupBoost TargetNeutral$126.00 ➝ $146.00
2/14/2020Morgan StanleyBoost TargetEqual Weight$136.00 ➝ $148.00
2/14/2020SunTrust BanksReiterated RatingHold$145.00
2/13/2020CfraUpgradeBuy ➝ Strong-Buy$147.00 ➝ $160.00
2/12/2020Bank of AmericaReiterated RatingHold$145.00
1/9/2020Raymond JamesInitiated CoverageMarket Perform
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.35 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 42 very positive mentions
  • 41 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 30 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 27 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 31 very positive mentions
  • 30 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 35 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 32 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 69 very positive mentions
  • 25 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 75 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 75 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Zoetis logo
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
Read More

Today's Range

Now: $164.84
Low: $163.53
High: $166.39

50 Day Range

MA: $178.52
Low: $163.52
High: $194.45

52 Week Range

Now: $164.84
Low: $144.80
High: $200.53

Volume

6,184,068 shs

Average Volume

2,552,173 shs

Market Capitalization

$74.37 billion

P/E Ratio

30.99

Dividend Yield

1.03%

Beta

0.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Zoetis?

The following Wall Street analysts have issued research reports on Zoetis in the last twelve months: Argus, Barclays PLC, BTIG Research, HSBC Holdings plc, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Piper Sandler, Stifel Nicolaus, StockNews.com, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for ZTS.

What is the current price target for Zoetis?

0 Wall Street analysts have set twelve-month price targets for Zoetis in the last year. Their average twelve-month price target is $215.22, suggesting a possible upside of 30.6%. Barclays PLC has the highest price target set, predicting ZTS will reach $230.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $196.00 for Zoetis in the next year.
View the latest price targets for ZTS.

What is the current consensus analyst rating for Zoetis?

Zoetis currently has 1 hold rating, 8 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZTS will outperform the market and that investors should add to their positions of Zoetis.
View the latest ratings for ZTS.

What other companies compete with Zoetis?

Other companies that are similar to Zoetis include AbbVie, Merck & Co., Inc., Pfizer, Bristol-Myers Squibb and Royalty Pharma. Learn More about companies similar to Zoetis.

How do I contact Zoetis' investor relations team?

Zoetis' physical mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company's listed phone number is (973) 822-7000 and its investor relations email address is [email protected]. The official website for Zoetis is www.zoetis.com. Learn More about contacing Zoetis investor relations.